{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:06:46Z","timestamp":1794672406909,"version":"4.9.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":116,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There is limited work on the impact of chemotherapy-induced nausea and vomiting (CINV) on quality of life (QoL) in adriamycin-cyclophosphamide (AC)\u2013treated patients with breast cancer. The objectives of the study were the following: (a) to confirm if symptoms of CINV led to lower QoL during AC; (b) to evaluate the pattern of changes in patients\u2019 QoL during multiple cycles of AC; and (c) to assess if the QoL in an earlier cycle affected the QoL in subsequent cycles of AC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>This is a secondary pooled data analysis that included 303 Chinese patients with breast cancer who received 1,177 cycles of adjuvant AC in three prospective antiemetic studies. QoL data were based on Functional Living Index\u2013emesis (FLIE) scored over three to four AC cycles. CINV symptoms assessed included \u201cno significant nausea\u201d (NSN), \u201csignificant nausea\u201d (SN), \u201cno vomiting\u201d (NoV), \u201cvomiting\u201d (V), and complete response (CR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Across all AC cycles, the mean scores for the FLIE nausea domain for patients who experienced NSN versus SN were 10.92 versus 53.92, respectively (p\u00a0&amp;lt;\u00a0.0001), with lower scores indicating better QoL; the mean scores for the FLIE vomiting domain for patients who experienced NoV versus V were 1.44 versus 19.11, respectively (p &amp;lt; .0001), with similar results across subsequent cycles. Analysis of the effect of the QoL in cycle 1 on the QoL of subsequent cycles revealed the following: for the nausea domain, among patients who had cycle 1 FLIE scores \u2265 versus &amp;lt; the mean, the corresponding scores in cycle 2 were 6.87 versus 36.71 (p\u00a0&amp;lt;\u00a0.0001); whereas those for cycle 3 were 7.07 versus 36.87 (p\u00a0&amp;lt;\u00a0.0001); and those for cycle 4 were 5.92 versus 21.48 (p\u00a0&amp;lt;\u00a0.0001). Similar findings were observed for the vomiting domain. Netupitant + palonosetron\u2013 or aprepitant\/olanzapine\u2013based antiemetics had significantly better QoL outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>CINV had a significant impact on the QoL of patients with breast cancer treated with AC over multiple cycles.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>In this post-hoc analysis of three prospective studies on chemotherapy-induced nausea and vomiting (CINV), quality of life (QoL) using contemporary antiemetic regimens in Chinese breast cancer patients receiving doxorubicin-cyclophosphamide (AC) was evaluated. During the first and subsequent AC cycles, QoL was significantly better for patients who did not experience vomiting or significant nausea. QoL in an earlier cycle affected the QoL in subsequent AC cycles. Furthermore, recent regimens involving olanzapine\/aprepitant or netupitant-palonosetron were associated with a positive impact in QoL. Antiemetic guideline-consistent practice and higher clinician awareness of the impact of CINV on QoL can further mitigate the negative effects of CINV on QoL<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13978","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T15:29:22Z","timestamp":1631546962000},"page":"e2288-e2296","source":"Crossref","is-referenced-by-count":19,"title":["Quality of Life Associated with Nausea and Vomiting from Anthracycline-Based Chemotherapy: A Pooled Data Analysis from Three Prospective Trials"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0863-8469","authenticated-orcid":false,"given":"Winnie","family":"Yeo","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong"},{"name":"State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong SAR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frankie K.F.","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong"},{"name":"State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong SAR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.H.","family":"Yip","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria A.","family":"Yeo","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leung","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.H.","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwai T.","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky T.C.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan H.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol C.H.","family":"Kwok","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Princess Margaret Hospital, Kowloon, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce J.S.","family":"Suen","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, Hong Kong Cancer Institute, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Molassiotis","sequence":"additional","affiliation":[{"name":"School of Nursing, The Hong Kong Polytechnic University, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,25]]},"reference":[{"key":"2022011918113583600_onco13978-bib-0001","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","article-title":"Chemotherapy-induced nausea and vomiting","volume":"358","author":"Hesketh","year":"2008","journal-title":"N Engl J Med"},{"key":"2022011918113583600_onco13978-bib-0002","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00520-006-0173-z","article-title":"Chemotherapy-induced nausea and vomiting\u2014incidence and impact on patient quality of life at community oncology settings","volume":"15","author":"Cohen","year":"2007","journal-title":"Supportive Care Cancer"},{"key":"2022011918113583600_onco13978-bib-0003","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00520-012-1493-9","article-title":"The impact of chemotherapy-related nausea on patients\u2019 nutritional status, psychological distress and quality of life","volume":"21","author":"Farrell","year":"2013","journal-title":"Support Care Cancer"},{"key":"2022011918113583600_onco13978-bib-0004","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00520-006-0109-7","article-title":"The impact of chemotherapy-induced nausea and vomiting on health-related quality of life","volume":"15","author":"Ballatori","year":"2007","journal-title":"Support Care Cancer"},{"key":"2022011918113583600_onco13978-bib-0005","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s00520-004-0662-x","article-title":"Chemotherapy-induced nausea and vomiting in routine practice: A European perspective","volume":"12","author":"Glaus","year":"2004","journal-title":"Support Care Cancer"},{"key":"2022011918113583600_onco13978-bib-0006","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00520-010-1073-9","article-title":"Chemotherapy-induced nausea and vomiting in daily clinical practice: A community hospital-based study","volume":"20","author":"Hilarius","year":"2012","journal-title":"Support Care Cancer"},{"key":"2022011918113583600_onco13978-bib-0007","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00520-010-0915-9","article-title":"Impact on daily functioning and indirect\/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population","volume":"19","author":"Haiderali","year":"2011","journal-title":"Support Care Cancer"},{"key":"2022011918113583600_onco13978-bib-0008","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl-Daum","year":"2006","journal-title":"J Clin Oncol"},{"key":"2022011918113583600_onco13978-bib-0009","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/cncr.23594","article-title":"How do patient expectancies, quality of life, and postchemotherapy nausea interrelate?","volume":"113","author":"Colagiuri","year":"2008","journal-title":"Cancer"},{"key":"2022011918113583600_onco13978-bib-0010","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00520-012-1574-9","article-title":"Nausea still the poor relation in antiemetic therapy? The impact on cancer patients\u2019 quality of life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster","volume":"21","author":"Pirri","year":"2013","journal-title":"Support Care Cancer"},{"key":"2022011918113583600_onco13978-bib-0011","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/s11096-016-0393-3","article-title":"Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life","volume":"38","author":"Abunahlah","year":"2016","journal-title":"Int J Clin Pharm"},{"key":"2022011918113583600_onco13978-bib-0012","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2217\/fon-2020-0187","article-title":"Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life","volume":"16","author":"Karthaus","year":"2020","journal-title":"Future Oncol"},{"key":"2022011918113583600_onco13978-bib-0013","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1056\/NEJM200005253422102","article-title":"Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy","volume":"342","author":"Italian Group for Antiemetic Research","year":"2000","journal-title":"N Engl J Med"},{"key":"2022011918113583600_onco13978-bib-0014","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1007\/s00520-012-1448-1","article-title":"Chemotherapy-induced nausea and vomiting in clinical practice: Impact on patients\u2019 quality of life","volume":"20","author":"Fern\u00e1ndez-Ortega","year":"2012","journal-title":"Support Care Cancer"},{"key":"2022011918113583600_onco13978-bib-0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1634\/theoncologist.8-2-187","article-title":"Chemotherapy-induced nausea and vomiting: The importance of acute antiemetic control","volume":"8","author":"Schnell","year":"2003","journal-title":"The Oncologist"},{"key":"2022011918113583600_onco13978-bib-0016","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-008-9957-9","article-title":"A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy","volume":"113","author":"Yeo","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"2022011918113583600_onco13978-bib-0017","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.breast.2020.01.005","article-title":"A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients","volume":"50","author":"Yeo","year":"2020","journal-title":"Breast"},{"key":"2022011918113583600_onco13978-bib-0018","doi-asserted-by":"crossref","DOI":"10.1136\/bmjspcare-2019-002037","article-title":"NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin","author":"Yeo","year":"2020","journal-title":"BMJ Support Palliat Care"},{"key":"2022011918113583600_onco13978-bib-0019","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s00520-003-0482-4","article-title":"Assessing the impact of chemotherapy-induced nausea and vomiting on patients\u2019 daily lives: A modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall","volume":"11","author":"Martin","year":"2003","journal-title":"Support Care Cancer"},{"key":"2022011918113583600_onco13978-bib-0020","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s00520-010-0982-y","article-title":"Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: A prospective, longitudinal, observational study","volume":"19","author":"Pirri","year":"2011","journal-title":"Support Care Cancer"},{"key":"2022011918113583600_onco13978-bib-0021","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00520-007-0343-7","article-title":"A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre","volume":"16","author":"Molassiotis","year":"2008","journal-title":"Support Care Cancer"},{"key":"2022011918113583600_onco13978-bib-0022","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.1997.15.1.116","article-title":"Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group","volume":"15","author":"Osoba","year":"1997","journal-title":"J Clin Oncol"},{"key":"2022011918113583600_onco13978-bib-0023","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000431256","article-title":"Role of psychosocial variables on chemotherapy-induced nausea and vomiting and health-related quality of life among cancer patients: A European study","volume":"84","author":"Grassi","year":"2015","journal-title":"Psychother Psychosom"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13978","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13978","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/12\/e2288\/42242701\/oncolo_26_12_e2288.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/12\/e2288\/42242701\/oncolo_26_12_e2288.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T18:18:53Z","timestamp":1642616333000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/12\/e2288\/6511644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,25]]},"references-count":23,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,9,25]]},"published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13978","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,9,25]]}}}